Rubin and Casperson warn misleading headlines distort hormone therapy risks
Updated
Updated · Medscape · May 10
Rubin and Casperson warn misleading headlines distort hormone therapy risks
4 articles · Updated · Medscape · May 10
They said a Menopause paper on therapy after age 65 lacked data on drug type, dose and route, while FDA-approved label changes removing black box warnings took effect on 12 February.
The doctors argued lumping vaginal, transdermal and oral hormones together wrongly inflates perceived danger and can lead clinicians to stop treatment or deny it to symptomatic patients.
They said stopping therapy can worsen bone loss, fractures, urinary tract infections and sleep, urging doctors to use nuanced, individual risk-benefit discussions rather than headline-driven decisions.
With hormone therapy warnings gone, are we entering a new era for women's health or just a new wave of medical confusion?
How can different hormone therapies carry vastly different risks, and what crucial details are the headlines ignoring?
Landmark FDA Decision in 2025: Black Box Warnings Lifted from Menopause Hormone Therapy After Two Decades
Overview
In November 2025, the FDA removed broad 'black box' warnings from menopause hormone therapy (MHT), marking a major change in women’s health care. This decision followed a thorough review of scientific evidence, which found that earlier studies like the Women’s Health Initiative (WHI) had key flaws—such as using older participants and outdated hormone formulations. Modern research shows that newer, lower-dose and transdermal MHT options can offer important benefits with fewer risks. The FDA’s move reflects a shift from blanket caution to a more balanced, evidence-based approach, aiming to improve access and support for women seeking menopause treatment.